Occupational Allergic Rhinitis: What Do We Know?

被引:0
|
作者
Mungan D. [1 ]
机构
[1] Department of Pulmonary Diseases, Division of Allergy and Immunology, School of Medicine, Ankara University, Ankara
关键词
Occupational allergy; Occupational asthma; Occupational rhinitis; Rhinitis; Work related rhinitis;
D O I
10.1007/s40521-014-0041-x
中图分类号
学科分类号
摘要
• The main objectives of the management of occupational rhinitis are, elimination of symptoms and prevention of development of asthma. • Management strategies include, environmental interventions (cessation or reducing the exposure to the causal agent) and appropriate pharmacologic treatment. • Drug therapy does not differ from non-occupational rhinitis. • Given the increased risk for occupational asthma in patients with occupational rhinitis, the most effective approach is complete avoidance of exposure to the offending agent. However, if complete cessation of exposure leads to adverse socio-economic measures, reduction in contact with the agent in combination with drug therapy can be considered. • Allergen immunotherapy (AIT) has been used for a few sensitizers in occupational allergic diseases. The use of AIT is very limited due to inadequate standardization of occupational allergens. Effective treatment of patients with occupational allergy by the use of AIT may allow workers to continue their work when exposure can not be avoided. The new technologies are expected to improve the quality and efficacy of specific immunotherapy in patients with occupational allergy in the future. © 2014, Springer International Publishing AG.
引用
收藏
页码:10 / 19
页数:9
相关论文
共 50 条
  • [41] How do we know what we know?
    Dhara, Arundhati
    CANADIAN FAMILY PHYSICIAN, 2021, 67 (11) : 851 - 852
  • [42] WHAT DO WE KNOW - WHAT SHALL WE DO - WHAT DO WE TELL
    Radstake, Timothy R.
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 48 - 49
  • [43] Allergen Immunotherapy (AIT) in Allergic Rhinitis: Long-Term Efficacy and the Development of Asthma. What Do We Know?
    Vidal C.
    Rodríguez del Río P.
    Tabar A.
    Moreno C.
    Current Treatment Options in Allergy, 2014, 1 (1) : 14 - 26
  • [44] Governance: What Do We Know, and How Do We Know It?
    Fukuyama, Francis
    ANNUAL REVIEW OF POLITICAL SCIENCE, VOL 19, 2016, 19 : 89 - 105
  • [45] What do we know and how do we really know it?
    Pearce, JL
    ACADEMY OF MANAGEMENT REVIEW, 2004, 29 (02): : 175 - 179
  • [46] Commentary: We still do not know what we do not know
    Coselli, Joseph S.
    JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2021, 161 (04): : 1191 - 1192
  • [47] Protein particles: What we know and what we do not know
    Ripple, Dean C.
    Dimitrova, Mariana N.
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2012, 101 (10) : 3568 - 3579
  • [48] What we know and what we do not know about DMN
    Figl, Kathrin
    Mendling, Jan
    Tokdemir, Gul
    Vanthienen, Jan
    ENTERPRISE MODELLING AND INFORMATION SYSTEMS ARCHITECTURES-AN INTERNATIONAL JOURNAL, 2018, 13
  • [49] MYELIN VESICLES - WHAT WE KNOW AND WHAT WE DO NOT KNOW
    SEDZIK, J
    BLAUROCK, AE
    JOURNAL OF NEUROSCIENCE RESEARCH, 1995, 41 (02) : 145 - 152
  • [50] Brain drain:: what we know and what we do not know
    Wachter, Bernd
    Formative Years of Scholars, 2006, 83 : 51 - 66